LAMICTAL ODT Drug Patent Profile

Name: LAMICTAL ODT Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Lamictal Odt patents expire, and when can generic versions of Lamictal Odt launch?

Lamictal Odt is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in LAMICTAL ODT is lamotrigine. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lamictal Odt

A generic version of LAMICTAL ODT was approved as lamotrigine by DR REDDYS LABS LTD on January 22^nd, 2009.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for LAMICTAL ODT?
What are the global sales for LAMICTAL ODT?
What is Average Wholesale Price for LAMICTAL ODT?

Summary for LAMICTAL ODT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	95
Patent Applications:	4,863
Drug Prices:	Drug price information for LAMICTAL ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAMICTAL ODT
DailyMed Link:	LAMICTAL ODT at DailyMed

Drug patent expirations by year for LAMICTAL ODT

Recent Clinical Trials for LAMICTAL ODT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioPharma Services Inc.	PHASE1
Desitin Arzneimittel GmbH	PHASE1
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all LAMICTAL ODT clinical trials

Pharmacology for LAMICTAL ODT

Drug Class	Anti-epileptic Agent Mood Stabilizer
Mechanism of Action	Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for LAMICTAL ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LAMICTAL ODT	Orally Disintegrating Tablets	lamotrigine	25 mg, 50 mg, 100 mg, and 200 mg	022251	1	2009-12-21

US Patents and Regulatory Information for LAMICTAL ODT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-001	May 8, 2009	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-004	May 8, 2009	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-002	May 8, 2009	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-003	May 8, 2009	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LAMICTAL ODT

See the table below for patents covering LAMICTAL ODT around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Argentina	068185		⤷ Start Trial
Australia	2008272871		⤷ Start Trial
Brazil	PI0814408	composições de lamotrigina em comprimido de desintegração oral	⤷ Start Trial
Canada	2693072	COMPOSITIONS DE COMPRIMÉ À DÉSINTÉGRATION PAR VOIE ORALE DE LAMOTRIGINE (Orally disintegrating tablet compositions of lamotrigine.)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration